Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487316 | 0.81 | FKBP1A (0.61) | MMP9MMP2FKBP1ARAB9AITGB1 | |
| SCHEMBL12084566 | 0.80 | ITGB1 (0.62) | MMP9MMP2FKBP1AITGB1ITGA4 | |
| SCHEMBL4253026 | 0.80 | ITGB1 (0.62) | MMP9MMP2FKBP1AITGB1ITGA4 | |
| SCHEMBL27537313 | 0.80 | FKBP1A (0.60) | MMP9MMP2FKBP1ARAB9AL3MBTL1 | |
| SCHEMBL5489489 | 0.79 | MAPK1 (0.50) | MMP9FKBP1ARAB9AL3MBTL1KDM4E | |
| SCHEMBL7070012 | 0.78 | FKBP1A (0.59) | MMP9MMP2FKBP1ARAB9AL3MBTL1 | |
| SCHEMBL7319731 | 0.78 | ITGB1 (0.58) | MMP9MMP2FKBP1ARAB9AL3MBTL1 | |
| SCHEMBL4251820 | 0.77 | MMP2 (0.56) | MMP9MMP2FKBP1AITGB1ITGA4 | |
| SCHEMBL12084433 | 0.77 | MMP2 (0.56) | MMP9MMP2FKBP1AITGB1ITGA4 | |
| SCHEMBL5491608 | 0.76 | FKBP1A (0.49) | FKBP1ARAB9AL3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | claimed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | claimed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7288526-B2 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, IL4I1 | MMP9 1231/4885MMP2 951/4885FKBP1A 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.